Document is current
Any future updates will be listed below
-
Authors
Lu, Dajun D.
Gu, Yayun
Li, Sheng-Wen A.
Barndt, Robert J.
Huang, Shih-Ming
Wang, Jehng-Kang
Su, Hui Chen
Johnson, Michael D.
Lin, Chen-Yong https://orcid.org/0000-0002-6391-2571
-
Funding
Funding for this research was provided by:
National Cancer Institute (CA 123223)
National Cancer Institute (CA 123223)
Ministry of National Defense Medical Affairs Bureau, Taiwan (MAB-108-079)
Chi Mei Medical Center (CMNDMC10703)
Chi Mei Medical Center (CMNDMC10807)
- License Information
-
More Information
Article History
Received: 17 November 2020
Accepted: 10 January 2021
First Online: 24 January 2021
Compliance with ethical standards
:
: CYL is an inventor on US patents #6,077,938 (Title: Monoclonal antibody to an 80-kDa protease) and #6,677,377 (Title: Structure based discovery of inhibitors of matriptase for the cancer diagnosis and therapy by detection and inhibition of matriptase activity) and MDJ and CYL are inventors on US patent #7,355,015 (Title: Matriptase, a serine protease and its applications).
